In:
Annual Review of Medicine, Annual Reviews, Vol. 61, No. 1 ( 2010-02-01), p. 317-328
Abstract:
The genomic era is changing the understanding of cancer, although translation of the vast amount of data available into decision-making algorithms is far from reality. Molecular profiling of hepatocellular carcinoma (HCC), the most common cause of death among cirrhotic patients and a fast-growing malignancy in Western countries, is enabling the advancement of novel approaches to disease diagnosis and management. Most HCCs arise on a cirrhotic liver, and predictably, an accurate genomic characterization will allow the identification of procarcinogenic signals amenable to selective targeting by chemopreventive strategies. Molecular diagnosis is currently feasible for small tumors, but it has not yet been formalized by scientific guidelines. Molecular treatment is a reality: Sorafenib confers unprecedented survival benefits in patients at advanced stages. Genomic information from tumor and nontumoral tissue will aid prognosis prediction and facilitate the identification of oncogene addiction loops, providing the opportunity for more personalized medicine.
Type of Medium:
Online Resource
ISSN:
0066-4219
,
1545-326X
DOI:
10.1146/med.2010.61.issue-1
DOI:
10.1146/annurev.med.080608.100623
Language:
English
Publisher:
Annual Reviews
Publication Date:
2010
detail.hit.zdb_id:
1481484-5
Permalink
